Hot Features
Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunot... Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine; and development agreement with the University of Pennsylvania School of Veterinary Medicine for the development of a metformin-based ophthalmic formulation. Curative Biotechnology, Inc. was founded in 1995 and is headquartered in Palm Beach Gardens, Florida. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.29631 | -24.7585227273 | 1.1968 | 1.2 | 0.65 | 1082 | 0.91386156 | CS |
| 4 | -0.64951 | -41.9038709677 | 1.55 | 1.58 | 0.65 | 686 | 1.17807339 | CS |
| 12 | -0.09951 | -9.951 | 1 | 1.99 | 0.59 | 1667 | 1.33361912 | CS |
| 26 | 0.89554 | 18091.7171717 | 0.00495 | 1.99 | 0.0032 | 87854 | 0.01831707 | CS |
| 52 | 0.88859 | 7467.14285714 | 0.0119 | 1.99 | 0.003 | 155600 | 0.01043568 | CS |
| 156 | 0.88209 | 4793.9673913 | 0.0184 | 1.99 | 0.0013 | 207673 | 0.01485873 | CS |
| 260 | 0.80842 | 878.049310307 | 0.09207 | 1.99 | 0.0013 | 337119 | 0.03844824 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.